4D Molecular Therapeutics Downgraded at Cantor Following Wet AMD Asset Data
4D Molecular Therapeutics Analyst Ratings
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
Cantor Fitzgerald Downgrades 4D Molecular Therapeutics(FDMT.US) to Hold Rating
Cantor Fitzgerald analyst Joshua Schimmer downgrades $4D Molecular Therapeutics(FDMT.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 52.2% and a total average
Cantor Fitzgerald Downgrades 4D Molecular Therapeutics to Neutral From Overweight
A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $36 to $82
On Sep 20, major Wall Street analysts update their ratings for $4D Molecular Therapeutics(FDMT.US)$, with price targets ranging from $36 to $82.Goldman Sachs analyst Salveen Richter maintains with a